Instilling confidence in ImmuneOnco's bispecific
The first data are dribbled out, but cross-trial comparisons look uninspiring.
Cardiff's questionable plan yields more questions
More data from onvansertib's phase 2 study fail to convince.
Celcuity's $5m pivot does the job
A Pfizer cast-off could become the company's first marketed drug.
Janux tries to improve on the masking approach
Meanwhile, investors await key clinical data.
5,000 patients later Roche scraps its TIGIT
Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals.
Scancell pivots back to a subgroup
The company claims a 69% response rate with iSCIB1+, but only in a “target population”.
